Rachel K. King, Chief Executive Officer
Before founding GlycoMimetics, Mrs. King was an Executive in Residence at New Enterprise Associates (NEA), one of the nation’s leading venture capital firms. Mrs. King came to NEA after serving as a Senior Vice President of Novartis Corporation. Before joining Novartis, Mrs. King spent ten years with Genetic Therapy, Inc. (GTI) from the company's startup phase, through its IPO and later acquisition by Novartis.  There she held various roles, including serving as the company's CEO. Mrs. King also worked previously at ALZA Corporation in Palo Alto, California and at Bain and Company in Boston. She received her B.A degree from Dartmouth College and her MBA from Harvard Business School. Mrs. King currently serves on the Board of the Biotechnology Industry Association (BIO).  At BIO, she is on the Executive Committee and the BioEthics Committee of the Board of Directors and is the immediate past Chair of the Emerging Companies Governing Body.  She is also a Member of the Maryland Life Sciences Advisory Board appointed by Governor Martin O’Malley.

John Magnani, Ph.D., Vice President and Chief Scientific Officer
John Magnani is an expert in carbohydrate biology having identified and characterized many carbohydrate tumor antigens and developed fundamental technology for the identification of functional carbohydrate epitopes. Dr. Magnani is the discoverer of Sialyl Lewis_a and its functions. He was the first to identify the binding domain to the selectins common to both Sialyl Lewis_a and Sialyl Lewis_x and used this information to develop potent selectin inhibitors. Prior to joining GlycoMimetics, Dr. Magnani founded and led GlycoTech Corporation as its President and CEO. Previously, he helped co-found the U.S. subsidiary of BioCarb and became its Vice President of Research. Dr. Magnani received his Ph.D. from Princeton University and then joined the Laboratory of Biological Pharmacology of the National Institute of Arthritis, Diabetes and Digestive and Kidney Diseases (NIADDK) of the National Institutes of Health. He remained at the NIH for ten years, finally serving as a tenured Research Chemist.

Helen Thackray, MD, FAAP, Vice President of Drug Development
Dr. Thackray joined GlycoMimetics in 2006.  Previously, she was Vice President of Clinical Product Development at Biosynexus, Inc. Prior to working at Biosynexus, Dr. Thackray served as a Medical Genetics Fellow at the National Human Genome Research Institute of the National Institutes of Health.  Concurrent to her position at GlycoMimetics, Dr. Thackray holds an appointment as Assistant Clinical Professor of Pediatrics at the George Washington University School of Medicine and is a practicing board-certified hospital-based pediatrician.  She completed a pediatrics residency at Children's National Medical Center in Washington, D.C., followed by a year as Pediatric Chief Resident and Adjunct Instructor in Pediatrics.  Dr. Thackray received her B.S from Stanford University and her M.D. from George Washington University School of Medicine.  She is a member of the Institutional Review Board of the National Center for Healthcare Statistics, and is a Fellow of the American Academy of Pediatrics.